Connect Biopharma Holdings (CNTB) Payables (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Payables for 7 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

• Quarterly Payables rose 427.05% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 427.05% YoY) and the FY2025 annual result came in at $2.0 million, up 474.27% from the prior year.
• Payables rose to $4.3 million in Q1 2026 per CNTB's latest filing, from $2.0 million in the prior quarter.
• Over the last five years, Payables for CNTB reached as high as $15.4 million in Q2 2022 and fell as low as $342000.0 in Q4 2024.
• A 5-year average of $5.3 million and a median of $2.3 million in 2025 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables plunged 84.52% — and 2025, when it soared 474.27%.
• Year by year, Payables stood at $11.7 million in 2022, then slumped by 81.1% to $2.2 million in 2023, then tumbled by 84.52% to $342000.0 in 2024, then surged by 474.27% to $2.0 million in 2025, then soared by 119.25% to $4.3 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $4.3 million, $2.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.